48 results about "Rhabdomyosarcoma" patented technology

The invention discloses a fluorescent probe and a kit for carrying out differential diagnosis on leukemia and bone marrow metastasis of rhabdomyosarcoma and neuroblastoma by using flow cytometry. The fluorescent probe comprises four fluorescence labeled antibodies; the four fluorescence labeled antibodies comprise a GD2 antibody, a CD90 antibody, a CD45 antibody and a CD56 antibody which take fluorescence labels; the different antibodies take the different fluorescence labels. The kit comprises a probe solution, a hemolytic agent, a phosphate buffer and a positive standard product. The fluorescent probe can be respectively and specifically combined with cells of the rhabdomyosarcoma and the neuroblastoma in bone marrow and original cells of acute leukemia; three tumor cells which are common in the child bone marrow, such as the bone marrow metastasis of the rhabdomyosarcoma and the neuroblastoma and the leukemia cells, can be rapidly and accurately identified by the flow cytometry, so as to guide clinical treatment; the application prospect is very good.

The invention relates to the field of medicines, and particularly relates to intratumoral injection for treating rhabdomyosarcoma. The intratumoral injection is prepared from the following componentsin parts by weight: 11-21 parts of tanshinol, 2-5 parts of 2,5-dimethoxy-4-Iodophenyl dimethylmethane-2-amine hydrochloride, and a pharmaceutically acceptable medicinal auxiliary material which is preferably prepared from mannitol, sodium acetate and injection water, wherein the tanshinol has a certain effect for resisting rhabdomyosarcoma; and no anti-tumor effect for a rhabdomyosarcoma cell lineand animal model is found in 2,5-dimethoxy-4-Iodophenyl dimethylmethane-2-amine hydrochloride, but cell and animal experiments indicate that 2,5-dimethoxy-4-Iodophenyl dimethylmethane-2-amine hydrochloride has a remarkable synergistic effect for the rhabdomyosarcoma resistance of tanshinol. The intratumoral injection has excellent safety in intratumoral injection.

The invention discloses an application of osteopetrosis-related transmembrane protein in a medicine for treatment or prevention of EV71 infection. The application comprises the following steps: firstly, expressing Ostml protein by an insect baculovirus expression system in an insect cell (SF9); purifying the Ostml protein by a nickel column affinity chromatography method; and finally, validating the antiviral effect of the Ostml protein in EV71-infected malignant rhabdomyosarcoma cells (RD cell). An experiment result proves that the purified Ostml protein is capable of inhibiting EV71 virus replication in mRNA level and protein level at certain concentration. The anti-EV71 virus effect of the osteopetrosis-related transmembrane protein (Ostml) is evaluated from protein purification and nucleus molecular level; a foundation is laid for further development and application. The protein is capable of directly inhibiting EV71 virus replication at proper concentration, is obvious in effect and free of a side effect on the cell, and simple and convenient to use. The medicine has the prospect that the medicine can be developed into an anti-EV71 virus effective medicine for clinical application.